#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=Identified mechanisms for target molecule elevation in CKD patients are either a decrease in renal excretion , an increase in endogenous production or both .
3-1	15-25	Identified	event[3]	new[3]	coref	3-11[8_3]
3-2	26-36	mechanisms	event[3]	new[3]	_	_
3-3	37-40	for	event[3]	new[3]	_	_
3-4	41-47	target	event[3]|abstract[5]	new[3]|new[5]	_	_
3-5	48-56	molecule	event[3]|substance|abstract[5]	new[3]|new|new[5]	_	_
3-6	57-66	elevation	event[3]|abstract[5]	new[3]|new[5]	_	_
3-7	67-69	in	event[3]|abstract[5]	new[3]|new[5]	_	_
3-8	70-73	CKD	event[3]|abstract[5]|abstract|person[7]	new[3]|new[5]|new|new[7]	coref|coref|coref|coref	5-16|10-2[92_7]|5-16|10-2[92_7]
3-9	74-82	patients	event[3]|abstract[5]|person[7]	new[3]|new[5]|new[7]	_	_
3-10	83-86	are	_	_	_	_
3-11	87-93	either	event[8]	giv[8]	_	_
3-12	94-95	a	event[8]	giv[8]	_	_
3-13	96-104	decrease	event[8]	giv[8]	_	_
3-14	105-107	in	event[8]	giv[8]	_	_
3-15	108-113	renal	event[8]|abstract|abstract[10]	giv[8]|new|new[10]	appos|coref|appos|coref	3-18[11_10]|4-39|3-18[11_10]|4-39
3-16	114-123	excretion	event[8]|abstract[10]	giv[8]|new[10]	_	_
3-17	124-125	,	_	_	_	_
3-18	126-128	an	abstract[11]	giv[11]	coref	4-38[34_11]
3-19	129-137	increase	abstract[11]	giv[11]	_	_
3-20	138-140	in	abstract[11]	giv[11]	_	_
3-21	141-151	endogenous	abstract[11]|abstract[12]	giv[11]|new[12]	coref	4-10[0_12]
3-22	152-162	production	abstract[11]|abstract[12]	giv[11]|new[12]	_	_
3-23	163-165	or	abstract[11]	giv[11]	_	_
3-24	166-170	both	abstract[11]	giv[11]	_	_
3-25	171-172	.	_	_	_	_

#Text=Thus , TMAO levels could result from variations in production levels ( including dietary precursor intake , TMA endogenous production from gut microbiota , TMA and TMAO intestinal absorption , and FMO3 enzymatic activity ) or from its renal excretion .
4-1	173-177	Thus	_	_	_	_
4-2	178-179	,	_	_	_	_
4-3	180-184	TMAO	abstract|abstract[14]	new|new[14]	coref|coref|coref|coref	4-10[17_14]|4-27|4-10[17_14]|4-27
4-4	185-191	levels	abstract[14]	new[14]	_	_
4-5	192-197	could	_	_	_	_
4-6	198-204	result	_	_	_	_
4-7	205-209	from	_	_	_	_
4-8	210-220	variations	abstract[15]	new[15]	_	_
4-9	221-223	in	abstract[15]	new[15]	_	_
4-10	224-234	production	abstract[15]|abstract|abstract[17]	new[15]|giv|giv[17]	coref|coref|coref|coref	4-18[22_0]|7-16[66_17]|4-18[22_0]|7-16[66_17]
4-11	235-241	levels	abstract[15]|abstract[17]	new[15]|giv[17]	_	_
4-12	242-243	(	abstract[15]|abstract[17]	new[15]|giv[17]	_	_
4-13	244-253	including	abstract[15]|abstract[17]	new[15]|giv[17]	_	_
4-14	254-261	dietary	abstract[15]|abstract[17]|abstract|event[20]	new[15]|giv[17]|new|new[20]	_	_
4-15	262-271	precursor	abstract[15]|abstract[17]|substance|event[20]	new[15]|giv[17]|new|new[20]	ana	5-27
4-16	272-278	intake	abstract[15]|abstract[17]|event[20]	new[15]|giv[17]|new[20]	_	_
4-17	279-280	,	abstract[15]|abstract[17]	new[15]|giv[17]	_	_
4-18	281-284	TMA	abstract[15]|abstract[17]|object|abstract[22]	new[15]|giv[17]|new|giv[22]	coref|coref	4-25|4-25
4-19	285-295	endogenous	abstract[15]|abstract[17]|abstract[22]	new[15]|giv[17]|giv[22]	_	_
4-20	296-306	production	abstract[15]|abstract[17]|abstract[22]	new[15]|giv[17]|giv[22]	_	_
4-21	307-311	from	abstract[15]|abstract[17]|abstract[22]	new[15]|giv[17]|giv[22]	_	_
4-22	312-315	gut	abstract[15]|abstract[17]|abstract[22]|abstract|object[24]	new[15]|giv[17]|giv[22]|new|new[24]	_	_
4-23	316-326	microbiota	abstract[15]|abstract[17]|abstract[22]|object[24]	new[15]|giv[17]|giv[22]|new[24]	_	_
4-24	327-328	,	abstract[15]|abstract[17]|abstract[22]	new[15]|giv[17]|giv[22]	_	_
4-25	329-332	TMA	abstract[15]|abstract[17]|abstract[22]|abstract	new[15]|giv[17]|giv[22]|giv	coref	25-17
4-26	333-336	and	abstract[15]|abstract[17]	new[15]|giv[17]	_	_
4-27	337-341	TMAO	abstract[15]|abstract[17]|abstract|abstract[28]	new[15]|giv[17]|giv|new[28]	coref|coref	5-12|5-12
4-28	342-352	intestinal	abstract[15]|abstract[17]|abstract|abstract[28]	new[15]|giv[17]|new|new[28]	_	_
4-29	353-363	absorption	abstract[15]|abstract[17]|abstract[28]	new[15]|giv[17]|new[28]	_	_
4-30	364-365	,	abstract[15]|abstract[17]	new[15]|giv[17]	_	_
4-31	366-369	and	abstract[15]|abstract[17]	new[15]|giv[17]	_	_
4-32	370-374	FMO3	abstract[15]|abstract[17]|substance|abstract[31]	new[15]|giv[17]|new|new[31]	ana|ana	4-38[0_31]|4-38[0_31]
4-33	375-384	enzymatic	abstract[15]|abstract[17]|place|abstract[31]	new[15]|giv[17]|new|new[31]	_	_
4-34	385-393	activity	abstract[15]|abstract[17]|abstract[31]	new[15]|giv[17]|new[31]	_	_
4-35	394-395	)	abstract[15]|abstract[17]	new[15]|giv[17]	_	_
4-36	396-398	or	abstract[15]|abstract[17]	new[15]|giv[17]	_	_
4-37	399-403	from	abstract[15]|abstract[17]	new[15]|giv[17]	_	_
4-38	404-407	its	abstract[15]|abstract[17]|abstract|abstract[34]	new[15]|giv[17]|giv|giv[34]	coref|coref	8-6[72_34]|8-6[72_34]
4-39	408-413	renal	abstract[15]|abstract[17]|abstract|abstract[34]	new[15]|giv[17]|giv|giv[34]	coref	5-31
4-40	414-423	excretion	abstract[15]|abstract[17]|abstract[34]	new[15]|giv[17]|giv[34]	_	_
4-41	424-425	.	_	_	_	_

#Text=This study was therefore designed to assess the exact changes in TMAO values according to CKD stages as determined by gold standard measurements of GFR and its potential modifications during renal metabolism .
5-1	426-430	This	abstract[35]	new[35]	coref	6-2[48_35]
5-2	431-436	study	abstract[35]	new[35]	_	_
5-3	437-440	was	_	_	_	_
5-4	441-450	therefore	_	_	_	_
5-5	451-459	designed	_	_	_	_
5-6	460-462	to	_	_	_	_
5-7	463-469	assess	_	_	_	_
5-8	470-473	the	abstract[36]	new[36]	_	_
5-9	474-479	exact	abstract[36]	new[36]	_	_
5-10	480-487	changes	abstract[36]	new[36]	_	_
5-11	488-490	in	abstract[36]	new[36]	_	_
5-12	491-495	TMAO	abstract[36]|object|abstract[38]	new[36]|giv|new[38]	coref|coref	6-9|6-9
5-13	496-502	values	abstract[36]|abstract[38]	new[36]|new[38]	_	_
5-14	503-512	according	_	_	_	_
5-15	513-515	to	_	_	_	_
5-16	516-519	CKD	abstract|abstract[40]	giv|new[40]	coref|coref|coref|coref	6-13|7-4[61_40]|6-13|7-4[61_40]
5-17	520-526	stages	abstract[40]	new[40]	_	_
5-18	527-529	as	_	_	_	_
5-19	530-540	determined	_	_	_	_
5-20	541-543	by	_	_	_	_
5-21	544-548	gold	substance|abstract[42]	new|new[42]	coref|coref	11-16|11-16
5-22	549-557	standard	abstract[42]	new[42]	_	_
5-23	558-570	measurements	abstract[42]	new[42]	_	_
5-24	571-573	of	abstract[42]	new[42]	_	_
5-25	574-577	GFR	abstract[42]|object	new[42]|new	coref	11-20
5-26	578-581	and	abstract[42]	new[42]	_	_
5-27	582-585	its	abstract[42]|substance|abstract[45]	new[42]|giv|new[45]	_	_
5-28	586-595	potential	abstract[42]|abstract[45]	new[42]|new[45]	_	_
5-29	596-609	modifications	abstract[42]|abstract[45]	new[42]|new[45]	_	_
5-30	610-616	during	abstract[42]|abstract[45]	new[42]|new[45]	_	_
5-31	617-622	renal	abstract[42]|abstract[45]|abstract|abstract[47]	new[42]|new[45]|giv|new[47]	coref|coref	9-18|9-18
5-32	623-633	metabolism	abstract[42]|abstract[45]|abstract[47]	new[42]|new[45]|new[47]	_	_
5-33	634-635	.	_	_	_	_

#Text=In the present study , we confirmed that TMAO is increased in CKD based on an inverse , although weak , correlation ( r2 = 0.388 ) between plasma TMAO and mGFR .
6-1	636-638	In	_	_	_	_
6-2	639-642	the	abstract[48]	giv[48]	coref	11-1[99_48]
6-3	643-650	present	abstract[48]	giv[48]	_	_
6-4	651-656	study	abstract[48]	giv[48]	_	_
6-5	657-658	,	_	_	_	_
6-6	659-661	we	person	acc	ana	7-9
6-7	662-671	confirmed	_	_	_	_
6-8	672-676	that	_	_	_	_
6-9	677-681	TMAO	abstract	giv	coref	6-29[58_0]
6-10	682-684	is	_	_	_	_
6-11	685-694	increased	_	_	_	_
6-12	695-697	in	_	_	_	_
6-13	698-701	CKD	abstract|abstract[52]	giv|new[52]	coref|coref|coref|coref	7-7|8-23[79_52]|7-7|8-23[79_52]
6-14	702-707	based	abstract[52]	new[52]	_	_
6-15	708-710	on	abstract[52]	new[52]	_	_
6-16	711-713	an	abstract[52]|abstract[53]	new[52]|new[53]	_	_
6-17	714-721	inverse	abstract[52]|abstract[53]	new[52]|new[53]	_	_
6-18	722-723	,	abstract[52]	new[52]	_	_
6-19	724-732	although	abstract[52]	new[52]	_	_
6-20	733-737	weak	abstract[52]|abstract[54]	new[52]|new[54]	coref	7-13[64_54]
6-21	738-739	,	abstract[52]|abstract[54]	new[52]|new[54]	_	_
6-22	740-751	correlation	abstract[52]|abstract[54]	new[52]|new[54]	_	_
6-23	752-753	(	_	_	_	_
6-24	754-756	r2	quantity	new	_	_
6-25	757-758	=	_	_	_	_
6-26	759-764	0.388	quantity	new	_	_
6-27	765-766	)	_	_	_	_
6-28	767-774	between	_	_	_	_
6-29	775-781	plasma	abstract|abstract[58]|abstract[59]	new|giv[58]|new[59]	coref|coref|coref|coref|coref|coref|coref|coref|coref	7-16[0_58]|12-4|14-8[127_59]|7-16[0_58]|12-4|14-8[127_59]|7-16[0_58]|12-4|14-8[127_59]
6-30	782-786	TMAO	abstract[58]|abstract[59]	giv[58]|new[59]	_	_
6-31	787-790	and	abstract[59]	new[59]	_	_
6-32	791-795	mGFR	abstract[59]|substance	new[59]|new	coref	14-10
6-33	796-797	.	_	_	_	_

#Text=Surprisingly , in all stages of CKD , we did not find any correlation between TMAO levels and its precursors , except a weak correlation with carnitine .
7-1	798-810	Surprisingly	_	_	_	_
7-2	811-812	,	_	_	_	_
7-3	813-815	in	_	_	_	_
7-4	816-819	all	abstract[61]	giv[61]	coref	11-11[103_61]
7-5	820-826	stages	abstract[61]	giv[61]	_	_
7-6	827-829	of	abstract[61]	giv[61]	_	_
7-7	830-833	CKD	abstract[61]|event	giv[61]|giv	coref	8-23
7-8	834-835	,	_	_	_	_
7-9	836-838	we	person	giv	ana	9-5
7-10	839-842	did	_	_	_	_
7-11	843-846	not	_	_	_	_
7-12	847-851	find	_	_	_	_
7-13	852-855	any	abstract[64]	giv[64]	coref	7-23[68_64]
7-14	856-867	correlation	abstract[64]	giv[64]	_	_
7-15	868-875	between	abstract[64]	giv[64]	_	_
7-16	876-880	TMAO	abstract[64]|abstract|abstract[66]	giv[64]|giv|giv[66]	coref|coref|coref|coref	8-4|11-5[102_66]|8-4|11-5[102_66]
7-17	881-887	levels	abstract[64]|abstract[66]	giv[64]|giv[66]	_	_
7-18	888-891	and	abstract[64]|abstract[66]	giv[64]|giv[66]	_	_
7-19	892-895	its	abstract[64]|abstract[66]|abstract[67]	giv[64]|giv[66]|new[67]	coref	25-16[221_67]
7-20	896-906	precursors	abstract[64]|abstract[66]|abstract[67]	giv[64]|giv[66]|new[67]	_	_
7-21	907-908	,	_	_	_	_
7-22	909-915	except	_	_	_	_
7-23	916-917	a	abstract[68]	giv[68]	coref	14-4[125_68]
7-24	918-922	weak	abstract[68]	giv[68]	_	_
7-25	923-934	correlation	abstract[68]	giv[68]	_	_
7-26	935-939	with	abstract[68]	giv[68]	_	_
7-27	940-949	carnitine	abstract[68]|substance	giv[68]|new	_	_
7-28	950-951	.	_	_	_	_

#Text=Measured clearances of TMAO showed a complete renal excretion of TMAO by glomerular filtration with a steady FE of 105 % during CKD , regardless of the stage .
8-1	952-960	Measured	abstract[70]	new[70]	coref	16-7[143_70]
8-2	961-971	clearances	abstract[70]	new[70]	_	_
8-3	972-974	of	abstract[70]	new[70]	_	_
8-4	975-979	TMAO	abstract[70]|abstract	new[70]|giv	coref	8-11
8-5	980-986	showed	_	_	_	_
8-6	987-988	a	abstract[72]	giv[72]	coref	10-7[94_72]
8-7	989-997	complete	abstract[72]	giv[72]	_	_
8-8	998-1003	renal	abstract[72]	giv[72]	_	_
8-9	1004-1013	excretion	abstract[72]	giv[72]	_	_
8-10	1014-1016	of	abstract[72]	giv[72]	_	_
8-11	1017-1021	TMAO	abstract[72]|abstract	giv[72]|giv	coref	9-21
8-12	1022-1024	by	_	_	_	_
8-13	1025-1035	glomerular	abstract|object[75]	new|new[75]	coref|coref|coref|coref	17-31|18-4[167_75]|17-31|18-4[167_75]
8-14	1036-1046	filtration	object[75]	new[75]	_	_
8-15	1047-1051	with	_	_	_	_
8-16	1052-1053	a	quantity[76]	new[76]	_	_
8-17	1054-1060	steady	quantity[76]	new[76]	_	_
8-18	1061-1063	FE	quantity[76]	new[76]	_	_
8-19	1064-1066	of	quantity[76]	new[76]	_	_
8-20	1067-1070	105	quantity[76]|quantity[77]	new[76]|new[77]	_	_
8-21	1071-1072	%	quantity[76]|quantity[77]	new[76]|new[77]	_	_
8-22	1073-1079	during	quantity[76]|quantity[77]	new[76]|new[77]	_	_
8-23	1080-1083	CKD	quantity[76]|quantity[77]|event|abstract[79]	new[76]|new[77]|giv|giv[79]	coref|coref	11-14|11-14
8-24	1084-1085	,	quantity[76]|quantity[77]|abstract[79]	new[76]|new[77]|giv[79]	_	_
8-25	1086-1096	regardless	quantity[76]|quantity[77]|abstract[79]	new[76]|new[77]|giv[79]	_	_
8-26	1097-1099	of	quantity[76]|quantity[77]|abstract[79]	new[76]|new[77]|giv[79]	_	_
8-27	1100-1103	the	quantity[76]|quantity[77]|abstract[79]|abstract[80]	new[76]|new[77]|giv[79]|new[80]	_	_
8-28	1104-1109	stage	quantity[76]|quantity[77]|abstract[79]|abstract[80]	new[76]|new[77]|giv[79]|new[80]	_	_
8-29	1110-1111	.	_	_	_	_

#Text=Unlike previous studies , we reported no evidence for effective contribution of tubular excretion or reabsorption during renal clearance of TMAO .
9-1	1112-1118	Unlike	_	_	_	_
9-2	1119-1127	previous	event[81]	new[81]	coref	12-13[114_81]
9-3	1128-1135	studies	event[81]	new[81]	_	_
9-4	1136-1137	,	_	_	_	_
9-5	1138-1140	we	person	giv	ana	10-5
9-6	1141-1149	reported	_	_	_	_
9-7	1150-1152	no	abstract[83]	new[83]	_	_
9-8	1153-1161	evidence	abstract[83]	new[83]	_	_
9-9	1162-1165	for	abstract[83]	new[83]	_	_
9-10	1166-1175	effective	abstract[83]|abstract[84]	new[83]|new[84]	_	_
9-11	1176-1188	contribution	abstract[83]|abstract[84]	new[83]|new[84]	_	_
9-12	1189-1191	of	abstract[83]|abstract[84]	new[83]|new[84]	_	_
9-13	1192-1199	tubular	abstract[83]|abstract[84]|abstract|abstract[86]	new[83]|new[84]|new|new[86]	coref|coref|coref|coref	25-6[218_86]|28-14|25-6[218_86]|28-14
9-14	1200-1209	excretion	abstract[83]|abstract[84]|abstract[86]	new[83]|new[84]|new[86]	_	_
9-15	1210-1212	or	abstract[83]|abstract[84]	new[83]|new[84]	_	_
9-16	1213-1225	reabsorption	abstract[83]|abstract[84]|abstract	new[83]|new[84]|new	coref	20-11[184_0]
9-17	1226-1232	during	_	_	_	_
9-18	1233-1238	renal	abstract|event[89]	giv|new[89]	coref|coref|coref|coref	15-13[0_89]|19-36|15-13[0_89]|19-36
9-19	1239-1248	clearance	event[89]	new[89]	_	_
9-20	1249-1251	of	event[89]	new[89]	_	_
9-21	1252-1256	TMAO	event[89]|object	new[89]|giv	coref	10-11
9-22	1257-1258	.	_	_	_	_

#Text=In hemodialysis patients , we confirmed a greater increase in TMAO even though FR was similar to that of urea .
10-1	1259-1261	In	_	_	_	_
10-2	1262-1274	hemodialysis	abstract|person[92]	new|giv[92]	coref|coref	22-10[196_92]|22-10[196_92]
10-3	1275-1283	patients	person[92]	giv[92]	_	_
10-4	1284-1285	,	_	_	_	_
10-5	1286-1288	we	person	giv	ana	15-5
10-6	1289-1298	confirmed	_	_	_	_
10-7	1299-1300	a	abstract[94]	giv[94]	_	_
10-8	1301-1308	greater	abstract[94]	giv[94]	_	_
10-9	1309-1317	increase	abstract[94]	giv[94]	_	_
10-10	1318-1320	in	abstract[94]	giv[94]	_	_
10-11	1321-1325	TMAO	abstract[94]|abstract	giv[94]|giv	ana	10-18[97_0]
10-12	1326-1330	even	_	_	_	_
10-13	1331-1337	though	_	_	_	_
10-14	1338-1340	FR	abstract	new	_	_
10-15	1341-1344	was	_	_	_	_
10-16	1345-1352	similar	_	_	_	_
10-17	1353-1355	to	_	_	_	_
10-18	1356-1360	that	abstract[97]	giv[97]	coref	11-8[0_97]
10-19	1361-1363	of	abstract[97]	giv[97]	_	_
10-20	1364-1368	urea	abstract[97]|substance	giv[97]|new	coref	19-14
10-21	1369-1370	.	_	_	_	_

#Text=This study investigated for the first time TMAO levels in all stages of CKD using gold standard measures of GFR .
11-1	1371-1375	This	abstract[99]	giv[99]	coref	14-1[124_99]
11-2	1376-1381	study	abstract[99]	giv[99]	_	_
11-3	1382-1394	investigated	_	_	_	_
11-4	1395-1398	for	_	_	_	_
11-5	1399-1402	the	abstract[102]	giv[102]	coref	13-1[117_102]
11-6	1403-1408	first	abstract[102]	giv[102]	_	_
11-7	1409-1413	time	time|abstract[102]	new|giv[102]	coref	24-14
11-8	1414-1418	TMAO	abstract|abstract[102]	giv|giv[102]	coref	12-3
11-9	1419-1425	levels	abstract[102]	giv[102]	_	_
11-10	1426-1428	in	abstract[102]	giv[102]	_	_
11-11	1429-1432	all	abstract[102]|abstract[103]	giv[102]|giv[103]	coref	14-18[132_103]
11-12	1433-1439	stages	abstract[102]|abstract[103]	giv[102]|giv[103]	_	_
11-13	1440-1442	of	abstract[102]|abstract[103]	giv[102]|giv[103]	_	_
11-14	1443-1446	CKD	abstract[102]|abstract[103]|abstract	giv[102]|giv[103]|giv	coref	12-7
11-15	1447-1452	using	_	_	_	_
11-16	1453-1457	gold	substance|abstract[106]	giv|new[106]	_	_
11-17	1458-1466	standard	abstract[106]	new[106]	_	_
11-18	1467-1475	measures	abstract[106]	new[106]	_	_
11-19	1476-1478	of	abstract[106]	new[106]	_	_
11-20	1479-1482	GFR	abstract[106]|object	new[106]|giv	coref	13-26[123_0]
11-21	1483-1484	.	_	_	_	_

#Text=Results of TMAO plasma concentrations in CKD were in good accordance with previous studies .
12-1	1485-1492	Results	abstract[108]	new[108]	coref	18-1[164_108]
12-2	1493-1495	of	abstract[108]	new[108]	_	_
12-3	1496-1500	TMAO	abstract[108]|substance|abstract[111]	new[108]|giv|new[111]	coref|coref	13-2|13-2
12-4	1501-1507	plasma	abstract[108]|substance|abstract[111]	new[108]|giv|new[111]	coref	13-3
12-5	1508-1522	concentrations	abstract[108]|abstract[111]	new[108]|new[111]	_	_
12-6	1523-1525	in	abstract[108]|abstract[111]	new[108]|new[111]	_	_
12-7	1526-1529	CKD	abstract[108]|abstract[111]|abstract	new[108]|new[111]|giv	coref	14-18
12-8	1530-1534	were	_	_	_	_
12-9	1535-1537	in	_	_	_	_
12-10	1538-1542	good	abstract[113]	new[113]	_	_
12-11	1543-1553	accordance	abstract[113]	new[113]	_	_
12-12	1554-1558	with	abstract[113]	new[113]	_	_
12-13	1559-1567	previous	abstract[113]|abstract[114]	new[113]|giv[114]	ana	13-10[0_114]
12-14	1568-1575	studies	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
12-15	1576-1577	.	_	_	_	_

#Text=Median TMAO plasma levels found herein were similar to those published by Stubbs et al. in 2015 , even though their data was based on estimated GFR .
13-1	1578-1584	Median	abstract[117]	giv[117]	coref	27-11[228_117]
13-2	1585-1589	TMAO	abstract|abstract[117]	giv|giv[117]	coref	14-8
13-3	1590-1596	plasma	abstract|abstract[117]	giv|giv[117]	coref	27-11
13-4	1597-1603	levels	abstract[117]	giv[117]	_	_
13-5	1604-1609	found	_	_	_	_
13-6	1610-1616	herein	_	_	_	_
13-7	1617-1621	were	_	_	_	_
13-8	1622-1629	similar	_	_	_	_
13-9	1630-1632	to	_	_	_	_
13-10	1633-1638	those	abstract	giv	ana	13-21
13-11	1639-1648	published	_	_	_	_
13-12	1649-1651	by	_	_	_	_
13-13	1652-1658	Stubbs	person	new	_	_
13-14	1659-1661	et	_	_	_	_
13-15	1662-1665	al.	_	_	_	_
13-16	1666-1668	in	_	_	_	_
13-17	1669-1673	2015	time	new	_	_
13-18	1674-1675	,	_	_	_	_
13-19	1676-1680	even	_	_	_	_
13-20	1681-1687	though	_	_	_	_
13-21	1688-1693	their	abstract|abstract[122]	giv|new[122]	coref|coref|coref|coref	14-13[0_122]|28-3[232_0]|14-13[0_122]|28-3[232_0]
13-22	1694-1698	data	abstract[122]	new[122]	_	_
13-23	1699-1702	was	_	_	_	_
13-24	1703-1708	based	_	_	_	_
13-25	1709-1711	on	_	_	_	_
13-26	1712-1721	estimated	object[123]	giv[123]	_	_
13-27	1722-1725	GFR	object[123]	giv[123]	_	_
13-28	1726-1727	.	_	_	_	_

#Text=Another study reported a negative correlation between TMAO and mGFR but both data sets were restricted to CKD stages 3 or more severe .
14-1	1728-1735	Another	abstract[124]	giv[124]	coref	15-8[135_124]
14-2	1736-1741	study	abstract[124]	giv[124]	_	_
14-3	1742-1750	reported	_	_	_	_
14-4	1751-1752	a	abstract[125]	giv[125]	coref	27-7[226_125]
14-5	1753-1761	negative	abstract[125]	giv[125]	_	_
14-6	1762-1773	correlation	abstract[125]	giv[125]	_	_
14-7	1774-1781	between	abstract[125]	giv[125]	_	_
14-8	1782-1786	TMAO	abstract[125]|abstract|abstract[127]	giv[125]|giv|giv[127]	coref|coref	15-16[139_0]|15-16[139_0]
14-9	1787-1790	and	abstract[125]|abstract[127]	giv[125]|giv[127]	_	_
14-10	1791-1795	mGFR	abstract[125]|abstract[127]|quantity	giv[125]|giv[127]|giv	coref	19-8
14-11	1796-1799	but	_	_	_	_
14-12	1800-1804	both	abstract[130]	new[130]	_	_
14-13	1805-1809	data	abstract|abstract[130]	giv|new[130]	coref	21-22[192_0]
14-14	1810-1814	sets	abstract[130]	new[130]	_	_
14-15	1815-1819	were	_	_	_	_
14-16	1820-1830	restricted	_	_	_	_
14-17	1831-1833	to	_	_	_	_
14-18	1834-1837	CKD	abstract|abstract[132]	giv|giv[132]	coref|coref|coref|coref	15-18|18-19[171_132]|15-18|18-19[171_132]
14-19	1838-1844	stages	abstract[132]	giv[132]	_	_
14-20	1845-1846	3	abstract[132]	giv[132]	_	_
14-21	1847-1849	or	_	_	_	_
14-22	1850-1854	more	_	_	_	_
14-23	1855-1861	severe	_	_	_	_
14-24	1862-1863	.	_	_	_	_

#Text=To the best of our knowledge , no study has performed urinary clearance measures of TMAO in CKD .
15-1	1864-1866	To	_	_	_	_
15-2	1867-1870	the	_	_	_	_
15-3	1871-1875	best	_	_	_	_
15-4	1876-1878	of	_	_	_	_
15-5	1879-1882	our	person|abstract[134]	giv|new[134]	ana|ana	17-22|17-22
15-6	1883-1892	knowledge	abstract[134]	new[134]	_	_
15-7	1893-1894	,	_	_	_	_
15-8	1895-1897	no	abstract[135]	giv[135]	coref	21-10[0_135]
15-9	1898-1903	study	abstract[135]	giv[135]	_	_
15-10	1904-1907	has	_	_	_	_
15-11	1908-1917	performed	_	_	_	_
15-12	1918-1925	urinary	object|abstract[138]	new|new[138]	coref|coref	31-12|31-12
15-13	1926-1935	clearance	event|abstract[138]	giv|new[138]	_	_
15-14	1936-1944	measures	abstract[138]	new[138]	_	_
15-15	1945-1947	of	abstract[138]	new[138]	_	_
15-16	1948-1952	TMAO	abstract[138]|abstract[139]	new[138]|giv[139]	coref	16-7[0_139]
15-17	1953-1955	in	abstract[138]|abstract[139]	new[138]|giv[139]	_	_
15-18	1956-1959	CKD	abstract[138]|abstract[139]|abstract	new[138]|giv[139]|giv	coref	18-19
15-19	1960-1961	.	_	_	_	_

#Text=Previously , Hai et al. published TMAO clearances in control subjects , reporting a higher clearance of TMAO compared to creatinine , suggesting an active secretion of TMAO .
16-1	1962-1972	Previously	_	_	_	_
16-2	1973-1974	,	_	_	_	_
16-3	1975-1978	Hai	person	new	_	_
16-4	1979-1981	et	_	_	_	_
16-5	1982-1985	al.	_	_	_	_
16-6	1986-1995	published	_	_	_	_
16-7	1996-2000	TMAO	abstract|abstract[143]	giv|giv[143]	coref|coref	16-18|16-18
16-8	2001-2011	clearances	abstract[143]	giv[143]	_	_
16-9	2012-2014	in	_	_	_	_
16-10	2015-2022	control	person[144]	new[144]	coref	31-32[263_144]
16-11	2023-2031	subjects	person[144]	new[144]	_	_
16-12	2032-2033	,	_	_	_	_
16-13	2034-2043	reporting	_	_	_	_
16-14	2044-2045	a	quantity[145]	new[145]	coref	19-1[173_145]
16-15	2046-2052	higher	quantity[145]	new[145]	_	_
16-16	2053-2062	clearance	quantity[145]	new[145]	_	_
16-17	2063-2065	of	quantity[145]	new[145]	_	_
16-18	2066-2070	TMAO	quantity[145]|abstract	new[145]|giv	coref	16-28
16-19	2071-2079	compared	_	_	_	_
16-20	2080-2082	to	_	_	_	_
16-21	2083-2093	creatinine	substance	new	ana	17-3
16-22	2094-2095	,	_	_	_	_
16-23	2096-2106	suggesting	_	_	_	_
16-24	2107-2109	an	abstract[148]	new[148]	coref	20-7[0_148]
16-25	2110-2116	active	abstract[148]	new[148]	_	_
16-26	2117-2126	secretion	abstract[148]	new[148]	_	_
16-27	2127-2129	of	abstract[148]	new[148]	_	_
16-28	2130-2134	TMAO	abstract[148]|abstract	new[148]|giv	coref	17-24
16-29	2135-2136	.	_	_	_	_

#Text=Due to its low molecular weight ( 75 Da ) and soluble non ionizable nature , with minimal protein-bound fraction , we consider TMAO to be entirely filtered through the glomerular basement membrane , which is the main known elimination route for TMAO .
17-1	2137-2140	Due	_	_	_	_
17-2	2141-2143	to	_	_	_	_
17-3	2144-2147	its	substance|abstract[151]	giv|new[151]	coref|coref	19-21|19-21
17-4	2148-2151	low	abstract[151]	new[151]	_	_
17-5	2152-2161	molecular	abstract[151]	new[151]	_	_
17-6	2162-2168	weight	abstract[151]	new[151]	_	_
17-7	2169-2170	(	_	_	_	_
17-8	2171-2173	75	quantity[152]	new[152]	_	_
17-9	2174-2176	Da	quantity[152]	new[152]	_	_
17-10	2177-2178	)	_	_	_	_
17-11	2179-2182	and	_	_	_	_
17-12	2183-2190	soluble	_	_	_	_
17-13	2191-2194	non	_	_	_	_
17-14	2195-2204	ionizable	abstract[153]	new[153]	_	_
17-15	2205-2211	nature	abstract[153]	new[153]	_	_
17-16	2212-2213	,	_	_	_	_
17-17	2214-2218	with	_	_	_	_
17-18	2219-2226	minimal	abstract[154]	new[154]	_	_
17-19	2227-2240	protein-bound	abstract[154]	new[154]	_	_
17-20	2241-2249	fraction	abstract[154]	new[154]	_	_
17-21	2250-2251	,	_	_	_	_
17-22	2252-2254	we	person	giv	ana	18-1
17-23	2255-2263	consider	_	_	_	_
17-24	2264-2268	TMAO	substance	giv	coref	17-43
17-25	2269-2271	to	_	_	_	_
17-26	2272-2274	be	_	_	_	_
17-27	2275-2283	entirely	_	_	_	_
17-28	2284-2292	filtered	_	_	_	_
17-29	2293-2300	through	_	_	_	_
17-30	2301-2304	the	object[159]	new[159]	_	_
17-31	2305-2315	glomerular	abstract|object[159]	giv|new[159]	coref	18-8
17-32	2316-2324	basement	place|object[159]	new|new[159]	_	_
17-33	2325-2333	membrane	object[159]	new[159]	_	_
17-34	2334-2335	,	_	_	_	_
17-35	2336-2341	which	_	_	_	_
17-36	2342-2344	is	_	_	_	_
17-37	2345-2348	the	abstract[161]	new[161]	_	_
17-38	2349-2353	main	abstract[161]	new[161]	_	_
17-39	2354-2359	known	abstract[161]	new[161]	_	_
17-40	2360-2371	elimination	abstract|abstract[161]	new|new[161]	_	_
17-41	2372-2377	route	abstract[161]	new[161]	_	_
17-42	2378-2381	for	abstract[161]	new[161]	_	_
17-43	2382-2386	TMAO	abstract[161]|substance	new[161]|giv	coref	18-7
17-44	2387-2388	.	_	_	_	_

#Text=Our results showed a likely complete TMAO glomerular filtration with a steady FE of TMAO , regardless of CKD stages .
18-1	2389-2392	Our	person|abstract[164]	giv|giv[164]	ana|coref|ana|coref	20-1|31-1[254_164]|20-1|31-1[254_164]
18-2	2393-2400	results	abstract[164]	giv[164]	_	_
18-3	2401-2407	showed	_	_	_	_
18-4	2408-2409	a	object[167]	giv[167]	_	_
18-5	2410-2416	likely	object[167]	giv[167]	_	_
18-6	2417-2425	complete	object[167]	giv[167]	_	_
18-7	2426-2430	TMAO	abstract|object[167]	giv|giv[167]	coref	18-15
18-8	2431-2441	glomerular	abstract|object[167]	giv|giv[167]	_	_
18-9	2442-2452	filtration	object[167]	giv[167]	_	_
18-10	2453-2457	with	object[167]	giv[167]	_	_
18-11	2458-2459	a	object[167]|quantity[168]	giv[167]|new[168]	coref	22-7[0_168]
18-12	2460-2466	steady	object[167]|quantity[168]	giv[167]|new[168]	_	_
18-13	2467-2469	FE	object[167]|quantity[168]	giv[167]|new[168]	_	_
18-14	2470-2472	of	object[167]|quantity[168]	giv[167]|new[168]	_	_
18-15	2473-2477	TMAO	object[167]|quantity[168]|abstract	giv[167]|new[168]|giv	coref	19-1
18-16	2478-2479	,	_	_	_	_
18-17	2480-2490	regardless	_	_	_	_
18-18	2491-2493	of	_	_	_	_
18-19	2494-2497	CKD	abstract|abstract[171]	giv|giv[171]	coref|coref	31-32|31-32
18-20	2498-2504	stages	abstract[171]	giv[171]	_	_
18-21	2505-2506	.	_	_	_	_

#Text=TMAO clearance was similar to that of mGFR , higher than that of urea , and lower than that of creatinine , suggesting that TMAO is neither secreted as creatinine nor reabsorbed as urea by renal tubules .
19-1	2507-2511	TMAO	abstract|event[173]	giv|giv[173]	ana|ana	19-6[174_0]|19-6[174_0]
19-2	2512-2521	clearance	event[173]	giv[173]	_	_
19-3	2522-2525	was	_	_	_	_
19-4	2526-2533	similar	_	_	_	_
19-5	2534-2536	to	_	_	_	_
19-6	2537-2541	that	abstract[174]	giv[174]	coref	19-25[0_174]
19-7	2542-2544	of	abstract[174]	giv[174]	_	_
19-8	2545-2549	mGFR	abstract[174]|object	giv[174]|giv	coref	22-21
19-9	2550-2551	,	abstract[174]	giv[174]	_	_
19-10	2552-2558	higher	abstract[174]	giv[174]	_	_
19-11	2559-2563	than	abstract[174]	giv[174]	_	_
19-12	2564-2568	that	abstract[174]	giv[174]	_	_
19-13	2569-2571	of	abstract[174]	giv[174]	_	_
19-14	2572-2576	urea	abstract[174]|substance	giv[174]|giv	_	_
19-15	2577-2578	,	abstract[174]	giv[174]	_	_
19-16	2579-2582	and	abstract[174]	giv[174]	_	_
19-17	2583-2588	lower	abstract[174]	giv[174]	_	_
19-18	2589-2593	than	_	_	_	_
19-19	2594-2598	that	_	_	_	_
19-20	2599-2601	of	_	_	_	_
19-21	2602-2612	creatinine	substance	giv	coref	29-18
19-22	2613-2614	,	_	_	_	_
19-23	2615-2625	suggesting	_	_	_	_
19-24	2626-2630	that	_	_	_	_
19-25	2631-2635	TMAO	abstract	giv	coref	20-14
19-26	2636-2638	is	_	_	_	_
19-27	2639-2646	neither	_	_	_	_
19-28	2647-2655	secreted	_	_	_	_
19-29	2656-2658	as	_	_	_	_
19-30	2659-2669	creatinine	_	_	_	_
19-31	2670-2673	nor	_	_	_	_
19-32	2674-2684	reabsorbed	_	_	_	_
19-33	2685-2687	as	_	_	_	_
19-34	2688-2692	urea	_	_	_	_
19-35	2693-2695	by	_	_	_	_
19-36	2696-2701	renal	abstract|object[180]	giv|new[180]	_	_
19-37	2702-2709	tubules	object[180]	new[180]	_	_
19-38	2710-2711	.	_	_	_	_

#Text=We however cannot exclude that the secretion rate exactly matched the reabsorption of TMAO .
20-1	2712-2714	We	person	giv	ana	26-1
20-2	2715-2722	however	_	_	_	_
20-3	2723-2729	cannot	_	_	_	_
20-4	2730-2737	exclude	_	_	_	_
20-5	2738-2742	that	_	_	_	_
20-6	2743-2746	the	abstract[183]	new[183]	coref	31-21[260_183]
20-7	2747-2756	secretion	abstract|abstract[183]	giv|new[183]	_	_
20-8	2757-2761	rate	abstract[183]	new[183]	_	_
20-9	2762-2769	exactly	_	_	_	_
20-10	2770-2777	matched	_	_	_	_
20-11	2778-2781	the	abstract[184]	giv[184]	_	_
20-12	2782-2794	reabsorption	abstract[184]	giv[184]	_	_
20-13	2795-2797	of	abstract[184]	giv[184]	_	_
20-14	2798-2802	TMAO	abstract[184]|abstract	giv[184]|giv	coref	22-6
20-15	2803-2804	.	_	_	_	_

#Text=Furthermore , high fractional reabsorption of sodium indicates that study participants had no tubular impairment , which reinforces the validity of these data .
21-1	2805-2816	Furthermore	_	_	_	_
21-2	2817-2818	,	_	_	_	_
21-3	2819-2823	high	abstract[186]	new[186]	_	_
21-4	2824-2834	fractional	abstract[186]	new[186]	_	_
21-5	2835-2847	reabsorption	abstract[186]	new[186]	_	_
21-6	2848-2850	of	abstract[186]	new[186]	_	_
21-7	2851-2857	sodium	abstract[186]|substance	new[186]|new	_	_
21-8	2858-2867	indicates	_	_	_	_
21-9	2868-2872	that	_	_	_	_
21-10	2873-2878	study	abstract|person[189]	giv|new[189]	coref|coref	31-7[255_0]|31-7[255_0]
21-11	2879-2891	participants	person[189]	new[189]	_	_
21-12	2892-2895	had	_	_	_	_
21-13	2896-2898	no	abstract[190]	new[190]	_	_
21-14	2899-2906	tubular	abstract[190]	new[190]	_	_
21-15	2907-2917	impairment	abstract[190]	new[190]	_	_
21-16	2918-2919	,	_	_	_	_
21-17	2920-2925	which	_	_	_	_
21-18	2926-2936	reinforces	_	_	_	_
21-19	2937-2940	the	abstract[191]	new[191]	_	_
21-20	2941-2949	validity	abstract[191]	new[191]	_	_
21-21	2950-2952	of	abstract[191]	new[191]	_	_
21-22	2953-2958	these	abstract[191]|abstract[192]	new[191]|giv[192]	_	_
21-23	2959-2963	data	abstract[191]|abstract[192]	new[191]|giv[192]	_	_
21-24	2964-2965	.	_	_	_	_

#Text=However , the IQR of TMAO FE showed that some patients exhibited higher or lower clearances of TMAO compared to mGFR ; especially in the control group where the median FE of TMAO was 103 % [ IQR 55 – 144 ] .
22-1	2966-2973	However	_	_	_	_
22-2	2974-2975	,	_	_	_	_
22-3	2976-2979	the	abstract[193]	new[193]	_	_
22-4	2980-2983	IQR	abstract[193]	new[193]	_	_
22-5	2984-2986	of	abstract[193]	new[193]	_	_
22-6	2987-2991	TMAO	abstract[193]|abstract	new[193]|giv	coref	22-18
22-7	2992-2994	FE	abstract[193]|quantity	new[193]|giv	_	_
22-8	2995-3001	showed	_	_	_	_
22-9	3002-3006	that	_	_	_	_
22-10	3007-3011	some	person[196]	giv[196]	_	_
22-11	3012-3020	patients	person[196]	giv[196]	_	_
22-12	3021-3030	exhibited	_	_	_	_
22-13	3031-3037	higher	abstract[197]	new[197]	_	_
22-14	3038-3040	or	abstract[197]	new[197]	_	_
22-15	3041-3046	lower	abstract[197]	new[197]	_	_
22-16	3047-3057	clearances	abstract[197]	new[197]	_	_
22-17	3058-3060	of	abstract[197]	new[197]	_	_
22-18	3061-3065	TMAO	abstract[197]|abstract	new[197]|giv	coref	22-33
22-19	3066-3074	compared	_	_	_	_
22-20	3075-3077	to	_	_	_	_
22-21	3078-3082	mGFR	quantity	giv	coref	24-17
22-22	3083-3084	;	_	_	_	_
22-23	3085-3095	especially	place[201]	new[201]	_	_
22-24	3096-3098	in	place[201]	new[201]	_	_
22-25	3099-3102	the	place[201]	new[201]	_	_
22-26	3103-3110	control	abstract|place[201]	new|new[201]	coref	31-30
22-27	3111-3116	group	place[201]	new[201]	_	_
22-28	3117-3122	where	_	_	_	_
22-29	3123-3126	the	quantity[202]	new[202]	coref	22-35[204_202]
22-30	3127-3133	median	quantity[202]	new[202]	_	_
22-31	3134-3136	FE	quantity[202]	new[202]	_	_
22-32	3137-3139	of	quantity[202]	new[202]	_	_
22-33	3140-3144	TMAO	quantity[202]|abstract	new[202]|giv	coref	24-6
22-34	3145-3148	was	_	_	_	_
22-35	3149-3152	103	quantity[204]	giv[204]	_	_
22-36	3153-3154	%	quantity[204]	giv[204]	_	_
22-37	3155-3156	[	quantity[204]	giv[204]	_	_
22-38	3157-3160	IQR	quantity[204]	giv[204]	_	_
22-39	3161-3163	55	quantity[204]	giv[204]	_	_
22-40	3164-3165	–	quantity[204]	giv[204]	_	_
22-41	3166-3169	144	quantity[204]|quantity	giv[204]|new	_	_
22-42	3170-3171	]	quantity[204]	giv[204]	_	_
22-43	3172-3173	.	_	_	_	_

#Text=This dispersion could be explained by several factors .
23-1	3174-3178	This	abstract[206]	new[206]	_	_
23-2	3179-3189	dispersion	abstract[206]	new[206]	_	_
23-3	3190-3195	could	_	_	_	_
23-4	3196-3198	be	_	_	_	_
23-5	3199-3208	explained	_	_	_	_
23-6	3209-3211	by	_	_	_	_
23-7	3212-3219	several	abstract[207]	new[207]	_	_
23-8	3220-3227	factors	abstract[207]	new[207]	_	_
23-9	3228-3229	.	_	_	_	_

#Text=First , urinary clearance of TMAO was not assessed at the exact same time points than mGFR , measured by inulin or iohexol clearance .
24-1	3230-3235	First	_	_	_	_
24-2	3236-3237	,	_	_	_	_
24-3	3238-3245	urinary	abstract[208]	new[208]	coref	24-23[215_208]
24-4	3246-3255	clearance	abstract[208]	new[208]	_	_
24-5	3256-3258	of	abstract[208]	new[208]	_	_
24-6	3259-3263	TMAO	abstract[208]|substance	new[208]|giv	coref	25-6
24-7	3264-3267	was	_	_	_	_
24-8	3268-3271	not	_	_	_	_
24-9	3272-3280	assessed	_	_	_	_
24-10	3281-3283	at	_	_	_	_
24-11	3284-3287	the	abstract[211]	new[211]	_	_
24-12	3288-3293	exact	abstract[211]	new[211]	_	_
24-13	3294-3298	same	abstract[211]	new[211]	_	_
24-14	3299-3303	time	abstract|abstract[211]	giv|new[211]	_	_
24-15	3304-3310	points	abstract[211]	new[211]	_	_
24-16	3311-3315	than	abstract[211]	new[211]	_	_
24-17	3316-3320	mGFR	abstract[211]|substance	new[211]|giv	coref	30-14
24-18	3321-3322	,	_	_	_	_
24-19	3323-3331	measured	_	_	_	_
24-20	3332-3334	by	_	_	_	_
24-21	3335-3341	inulin	substance	new	_	_
24-22	3342-3344	or	_	_	_	_
24-23	3345-3352	iohexol	substance|event[215]	new|giv[215]	_	_
24-24	3353-3362	clearance	event[215]	giv[215]	_	_
24-25	3363-3364	.	_	_	_	_

#Text=Second , the variability of TMAO excretion could also be related to the amount of ingested TMA precursors .
25-1	3365-3371	Second	_	_	_	_
25-2	3372-3373	,	_	_	_	_
25-3	3374-3377	the	abstract[216]	new[216]	_	_
25-4	3378-3389	variability	abstract[216]	new[216]	_	_
25-5	3390-3392	of	abstract[216]	new[216]	_	_
25-6	3393-3397	TMAO	abstract[216]|abstract|abstract[218]	new[216]|giv|giv[218]	coref|coref|coref|coref	27-14|31-22[0_218]|27-14|31-22[0_218]
25-7	3398-3407	excretion	abstract[216]|abstract[218]	new[216]|giv[218]	_	_
25-8	3408-3413	could	_	_	_	_
25-9	3414-3418	also	_	_	_	_
25-10	3419-3421	be	_	_	_	_
25-11	3422-3429	related	_	_	_	_
25-12	3430-3432	to	_	_	_	_
25-13	3433-3436	the	quantity[219]	new[219]	_	_
25-14	3437-3443	amount	quantity[219]	new[219]	_	_
25-15	3444-3446	of	quantity[219]	new[219]	_	_
25-16	3447-3455	ingested	quantity[219]|abstract[221]	new[219]|giv[221]	_	_
25-17	3456-3459	TMA	quantity[219]|abstract|abstract[221]	new[219]|giv|giv[221]	_	_
25-18	3460-3470	precursors	quantity[219]|abstract[221]	new[219]|giv[221]	_	_
25-19	3471-3472	.	_	_	_	_

#Text=We unfortunately did not administer standardized meals to avoid this bias .
26-1	3473-3475	We	person	giv	ana	27-3
26-2	3476-3489	unfortunately	_	_	_	_
26-3	3490-3493	did	_	_	_	_
26-4	3494-3497	not	_	_	_	_
26-5	3498-3508	administer	_	_	_	_
26-6	3509-3521	standardized	object[223]	new[223]	_	_
26-7	3522-3527	meals	object[223]	new[223]	_	_
26-8	3528-3530	to	_	_	_	_
26-9	3531-3536	avoid	_	_	_	_
26-10	3537-3541	this	abstract[224]	new[224]	_	_
26-11	3542-3546	bias	abstract[224]	new[224]	_	_
26-12	3547-3548	.	_	_	_	_

#Text=Yet , we did not find a significant correlation between plasma levels of TMAO and total protein intake .
27-1	3549-3552	Yet	_	_	_	_
27-2	3553-3554	,	_	_	_	_
27-3	3555-3557	we	person	giv	ana	30-1
27-4	3558-3561	did	_	_	_	_
27-5	3562-3565	not	_	_	_	_
27-6	3566-3570	find	_	_	_	_
27-7	3571-3572	a	abstract[226]	giv[226]	_	_
27-8	3573-3584	significant	abstract[226]	giv[226]	_	_
27-9	3585-3596	correlation	abstract[226]	giv[226]	_	_
27-10	3597-3604	between	abstract[226]	giv[226]	_	_
27-11	3605-3611	plasma	abstract[226]|abstract|abstract[228]	giv[226]|giv|giv[228]	_	_
27-12	3612-3618	levels	abstract[226]|abstract[228]	giv[226]|giv[228]	_	_
27-13	3619-3621	of	abstract[226]|abstract[228]	giv[226]|giv[228]	_	_
27-14	3622-3626	TMAO	abstract[226]|abstract[228]|substance	giv[226]|giv[228]|giv	coref	28-26
27-15	3627-3630	and	abstract[226]|abstract[228]	giv[226]|giv[228]	_	_
27-16	3631-3636	total	abstract[226]|abstract[228]|event[231]	giv[226]|giv[228]|new[231]	_	_
27-17	3637-3644	protein	abstract[226]|abstract[228]|substance|event[231]	giv[226]|giv[228]|new|new[231]	_	_
27-18	3645-3651	intake	abstract[226]|abstract[228]|event[231]	giv[226]|giv[228]|new[231]	_	_
27-19	3652-3653	.	_	_	_	_

#Text=Moreover , several studies in animal or cellular models have shown involvement of tubular transporters such as organic cation transporter 2 ( OCT2 ) in TMAO cellular uptake and efflux .
28-1	3654-3662	Moreover	_	_	_	_
28-2	3663-3664	,	_	_	_	_
28-3	3665-3672	several	event[232]	giv[232]	_	_
28-4	3673-3680	studies	event[232]	giv[232]	_	_
28-5	3681-3683	in	event[232]	giv[232]	_	_
28-6	3684-3690	animal	event[232]|animal	giv[232]|new	_	_
28-7	3691-3693	or	event[232]	giv[232]	_	_
28-8	3694-3702	cellular	event[232]|abstract[234]	giv[232]|new[234]	_	_
28-9	3703-3709	models	event[232]|abstract[234]	giv[232]|new[234]	_	_
28-10	3710-3714	have	_	_	_	_
28-11	3715-3720	shown	_	_	_	_
28-12	3721-3732	involvement	abstract[235]	new[235]	_	_
28-13	3733-3735	of	abstract[235]	new[235]	_	_
28-14	3736-3743	tubular	abstract[235]|abstract|abstract[237]	new[235]|giv|new[237]	_	_
28-15	3744-3756	transporters	abstract[235]|abstract[237]	new[235]|new[237]	_	_
28-16	3757-3761	such	abstract[235]|abstract[237]	new[235]|new[237]	_	_
28-17	3762-3764	as	abstract[235]|abstract[237]	new[235]|new[237]	_	_
28-18	3765-3772	organic	abstract[235]|abstract[237]|person[239]	new[235]|new[237]|new[239]	_	_
28-19	3773-3779	cation	abstract[235]|abstract[237]|animal|person[239]	new[235]|new[237]|new|new[239]	_	_
28-20	3780-3791	transporter	abstract[235]|abstract[237]|person[239]	new[235]|new[237]|new[239]	_	_
28-21	3792-3793	2	abstract[235]|abstract[237]|person[239]	new[235]|new[237]|new[239]	_	_
28-22	3794-3795	(	_	_	_	_
28-23	3796-3800	OCT2	object	new	_	_
28-24	3801-3802	)	_	_	_	_
28-25	3803-3805	in	_	_	_	_
28-26	3806-3810	TMAO	abstract|abstract[243]	giv|new[243]	coref|coref	30-6|30-6
28-27	3811-3819	cellular	abstract|abstract[243]	new|new[243]	_	_
28-28	3820-3826	uptake	abstract[243]	new[243]	_	_
28-29	3827-3830	and	_	_	_	_
28-30	3831-3837	efflux	abstract	new	ana	29-1
28-31	3838-3839	.	_	_	_	_

#Text=This , however , has not been confirmed in humans unlike what has been previously described for creatinine .
29-1	3840-3844	This	abstract	giv	_	_
29-2	3845-3846	,	_	_	_	_
29-3	3847-3854	however	_	_	_	_
29-4	3855-3856	,	_	_	_	_
29-5	3857-3860	has	_	_	_	_
29-6	3861-3864	not	_	_	_	_
29-7	3865-3869	been	_	_	_	_
29-8	3870-3879	confirmed	_	_	_	_
29-9	3880-3882	in	_	_	_	_
29-10	3883-3889	humans	person[246]	new[246]	_	_
29-11	3890-3896	unlike	person[246]	new[246]	_	_
29-12	3897-3901	what	person[246]	new[246]	_	_
29-13	3902-3905	has	_	_	_	_
29-14	3906-3910	been	_	_	_	_
29-15	3911-3921	previously	_	_	_	_
29-16	3922-3931	described	_	_	_	_
29-17	3932-3935	for	_	_	_	_
29-18	3936-3946	creatinine	substance	giv	_	_
29-19	3947-3948	.	_	_	_	_

#Text=We observed that elevation of TMAO is mostly due to a decrease in mGFR rather than tubular dysfunction .
30-1	3949-3951	We	person	giv	_	_
30-2	3952-3960	observed	_	_	_	_
30-3	3961-3965	that	abstract[249]	new[249]	_	_
30-4	3966-3975	elevation	abstract[249]	new[249]	_	_
30-5	3976-3978	of	abstract[249]	new[249]	_	_
30-6	3979-3983	TMAO	abstract[249]|abstract	new[249]|giv	coref	31-21
30-7	3984-3986	is	_	_	_	_
30-8	3987-3993	mostly	_	_	_	_
30-9	3994-3997	due	_	_	_	_
30-10	3998-4000	to	_	_	_	_
30-11	4001-4002	a	event[251]	new[251]	_	_
30-12	4003-4011	decrease	event[251]	new[251]	_	_
30-13	4012-4014	in	event[251]	new[251]	_	_
30-14	4015-4019	mGFR	event[251]|quantity	new[251]|giv	_	_
30-15	4020-4026	rather	_	_	_	_
30-16	4027-4031	than	_	_	_	_
30-17	4032-4039	tubular	abstract[253]	new[253]	_	_
30-18	4040-4051	dysfunction	abstract[253]	new[253]	_	_
30-19	4052-4053	.	_	_	_	_

#Text=These results are in line with another recent study reporting that urinary TMAO/creatinine ratios ( used as a surrogate of TMAO excretion rate ) were not significantly different between control and CKD subjects .
31-1	4054-4059	These	abstract[254]	giv[254]	_	_
31-2	4060-4067	results	abstract[254]	giv[254]	_	_
31-3	4068-4071	are	_	_	_	_
31-4	4072-4074	in	_	_	_	_
31-5	4075-4079	line	_	_	_	_
31-6	4080-4084	with	_	_	_	_
31-7	4085-4092	another	abstract[255]	giv[255]	_	_
31-8	4093-4099	recent	abstract[255]	giv[255]	_	_
31-9	4100-4105	study	abstract[255]	giv[255]	_	_
31-10	4106-4115	reporting	_	_	_	_
31-11	4116-4120	that	_	_	_	_
31-12	4121-4128	urinary	person|substance[257]	giv|new[257]	_	_
31-13	4129-4144	TMAO/creatinine	substance[257]	new[257]	_	_
31-14	4145-4151	ratios	_	_	_	_
31-15	4152-4153	(	_	_	_	_
31-16	4154-4158	used	_	_	_	_
31-17	4159-4161	as	_	_	_	_
31-18	4162-4163	a	_	_	_	_
31-19	4164-4173	surrogate	_	_	_	_
31-20	4174-4176	of	_	_	_	_
31-21	4177-4181	TMAO	abstract|abstract[260]	giv|giv[260]	_	_
31-22	4182-4191	excretion	abstract|abstract[260]	giv|giv[260]	_	_
31-23	4192-4196	rate	abstract[260]	giv[260]	_	_
31-24	4197-4198	)	_	_	_	_
31-25	4199-4203	were	_	_	_	_
31-26	4204-4207	not	_	_	_	_
31-27	4208-4221	significantly	_	_	_	_
31-28	4222-4231	different	_	_	_	_
31-29	4232-4239	between	_	_	_	_
31-30	4240-4247	control	abstract	giv	_	_
31-31	4248-4251	and	_	_	_	_
31-32	4252-4255	CKD	abstract|person[263]	giv|giv[263]	_	_
31-33	4256-4264	subjects	person[263]	giv[263]	_	_
31-34	4265-4266	.	_	_	_	_
